Skip to main content

Day: March 17, 2025

Natural Gas Services Group, Inc. Reports Fourth Quarter and Year-End 2024 Financial and Operating Results; Provides 2025 Guidance

Midland, Texas, March 17, 2025 (GLOBE NEWSWIRE) — Natural Gas Services Group, Inc. (“NGS” or the “Company”) (NYSE:NGS), a leading provider of natural gas compression equipment, technology, and services to the energy industry, today announced financial results for the three months and year-ended December 31, 2024. The Company also provided guidance for its full year 2025, anticipating significant top- and bottom-line growth with strong momentum moving into 2026. Fourth Quarter and Full Year 2024 HighlightsRental revenue of $38.2 million for the fourth quarter and $144.2 million for the full year 2024, representing increases of 21% and 36%, respectively, compared to the prior year comparable periods.Net income of $2.9 million or $0.23 per diluted share for the fourth quarter and $17.2 million or $1.37 per diluted share for the...

Continue reading

Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. “Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year. We remain optimistic about the long-term growth outlook of Akoya’s leading spatial biology solutions,” said Brian McKelligon, CEO of Akoya. “In 2024, Akoya achieved multiple milestones, including expanding our market-leading installed base to 1,330 instruments, launching our Manufacturing Center of Excellence...

Continue reading

Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results

FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal second quarter ended January 31, 2025, with sequential quarter improvement in revenue, gross margin and operating profit / loss. Financial HighlightsThe Company’s second-quarter gross margin percentage of 52% increased sequentially from 37% during Q1 2025 and increased from 49% during the second quarter of the prior year. These improvements were driven by change in revenues, cost efficiency actions completed, and mix of products sold. The Enzo Life Sciences Products segment, which excludes discontinued operations and Corporate overhead, achieved a $0.5 million operating profit during Q2 FY25, a $2M sequential improvement compared to a $1.5 operating loss during Q1 FY25,...

Continue reading

Interparfums, Inc. Announces Acquisition of the Goutal Brand

NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) — Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced that its subsidiary, Interparfums SA, has acquired all worldwide intellectual property rights relating to Maison Goutal held by Amorepacific Europe. Amorepacific Europe will continue to operate the Goutal Brand under a license agreement for a set duration. Interparfums SA will develop the brand from 2026 onwards, together with its licensee. Created by Annick Goutal in 1981, the eponymous brand positioned itself from the start in the exclusive high-end segment with the launch of the L’Eau d’Hadrien line and the opening of a first boutique on Rue de Bellechasse in Paris. Known for refined and poetic creations, Goutal successively developed a wide range of perfume, bath and home fragrance lines, marketed...

Continue reading

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia expected in 2025 Initiation of U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis expected in 2025 Full year 2025 total revenue guidance of $118 to $128 million SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. “2025 is shaping up to be a pivotal year for Gyre across both our commercial-stage...

Continue reading

Baltic Horizon Fund completed the sale of Meraki Business Home in Vilnius, Lithuania

The owner of Meraki Business Home in Vilnius, BH Meraki UAB, an SPV of Baltic Horizon Fund, closed a transaction at the end of last week, in accordance with which Groa Real Estate Opportunity Fund UAB, a fund managed by Groa Capital purchased Meraki Business Home in Vilnius, Lithuania. The sales price of the asset was approximately EUR 16 million. The proceeds of the transaction will be used to redeem EUR 3 million of Baltic Horizon Fund bonds and repay the loan from Bigbank. Baltic Horizon Fund informed the investors about the signing of the sale and purchase agreement via a stock exchange announcement published on 7 March 2025: https://view.news.eu.nasdaq.com/view?id=b44b29e9e4e39243051682af0fe3b84f5&lang=en&src=listed. For additional information, please contact: Tarmo Karotam Baltic Horizon Fund manager E-mail tarmo.karotam@nh-cap.com...

Continue reading

Baltic Horizon Fund completed the sale of Meraki Business Home in Vilnius, Lithuania

The owner of Meraki Business Home in Vilnius, BH Meraki UAB, an SPV of Baltic Horizon Fund, closed a transaction at the end of last week, in accordance with which Groa Real Estate Opportunity Fund UAB, a fund managed by Groa Capital purchased Meraki Business Home in Vilnius, Lithuania. The sales price of the asset was approximately EUR 16 million. The proceeds of the transaction will be used to redeem EUR 3 million of Baltic Horizon Fund bonds and repay the loan from Bigbank. Baltic Horizon Fund informed the investors about the signing of the sale and purchase agreement via a stock exchange announcement published on 7 March 2025: https://view.news.eu.nasdaq.com/view?id=b44b29e9e4e39243051682af0fe3b84f5&lang=en&src=listed. For additional information, please contact: Tarmo Karotam Baltic Horizon Fund manager E-mail tarmo.karotam@nh-cap.com...

Continue reading

Gray Stations Add Local News Live to Daily Programming Lineup

ATLANTA, March 17, 2025 (GLOBE NEWSWIRE) — Local News Live’s signature afternoon newscast joins the programming lineup on 37 of Gray Media’s local television stations starting today. The one-hour newscast featuring top stories from local journalists in Gray newsrooms across the country will air weekdays at 2:00 p.m. (ET) in most markets. This expansion means Local News Live now airs Monday through Friday in a total of 46 television markets and reaches more than 19 million households according to Nielsen. Local News Live Anchor and National Correspondent Debra Alfarone leads the program with live coverage of breaking news and local views on the day’s biggest stories from reporters across Gray’s 113 markets. Alfarone also fronts a popular franchise “The Good Side,” highlighting solutions-based stories and people who are making a...

Continue reading

Nilfisk implements changes to executive management

Chief Financial Officer Reinhard Mayer, a member of the Executive Management team, is by mutual agreement stepping down and will leave Nilfisk Holding A/S on March 18, 2025. Peter Nilsson, Chair of the Board of Directors, comments: –    During Reinhard’s tenure, he significantly strengthened our financial position. He made the balance sheet more resilient by delivering a substantial reduction in net interest-bearing debt, increasing profitability and EBITDA-margin, and achieving the highest gross profit margin since the listing in 2017. He also introduced new financial instruments including the successful completion of the promissory note Schuldschein loan. On behalf of the Board, I’d like to thank Reinhard for his valuable contribution”. Jon Sintorn, Chief Executive Officer, comments:–    “Reinhard has been a key contributor...

Continue reading

2G Engineering– Everaxis, From Outer Space to the Deepest Seas

Paris – France Everaxis, a leading global player in high-precision rotating solutions, announced the acquisition of 2G Engineering, a strategic move that aligns with its accelerated growth strategy and ambition to expand its presence in the US market. The acquisition of 2G Engineering complements Everaxis’ strong organic growth with acquisitive growth, expanding capabilities while staying true to its core expertise. The focus is on expanding our U.S. presence and creating a balanced footprint between the U.S. and global markets. We are highly selective in the companies we choose to partner with, ensuring they align with our business model — highly engineered solutions with strong growth potential. “2G Engineering has selected Everaxis as a partner for the future. Everaxis has a strong reputation for quality products in the aerospace...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.